pharmaphorum

AUGUST 4, 2020

AstraZeneca has bought an exclusive global licence to develop and market RXC006, a porcupine inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Redx will receive up to $17m in early payments between signing the deal and the successful start of the first clinical trial.

Drugs 109

Drugs Clinical Trials Clinical Trials Pharma Companies 109

pharmaphorum

DECEMBER 15, 2021

Dialogue requires humility on the drug company’s side—accepting that sometimes we are wrong about matters we think we understand—and trust on the patients’ side that representatives of large, for-profit entities really have come to listen. Previously, Anthony served as the Global Head of Patient Insights, Solutions and Outcomes at Sanofi.

Pharma Companies 145

Pharma Companies Development Medicine Drugs 145

Outsourcing Pharma

JULY 27, 2020

Elucid Digital Healthâs Pill Connect is designed to enable CROs and pharma companies to monitor patient adherence during a clinical trial.

Pharma Companies 52

Pharma Companies Clinical Trials Clinical Trials Drugs 52

pharmaphorum

JANUARY 24, 2022

Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Radiology 111

Radiology Marketing Genome Genomics 111

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. physIQ has a portfolio of FDA-cleared digital biomarkers and a medical-grade platform that can transform raw sensor data into clinical insight.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

pharmaphorum

NOVEMBER 3, 2022

As we strive to improve the medical product development process and speed the development of effective new therapies to patients, digital health solutions are becoming increasingly available, affordable, and anticipated in healthcare settings by patients, clinicians, and caregivers alike, driving expectations for trial participants.

Clinical Trials 81

Clinical Trials Clinical Trials Trials Medicine 81

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

MARCH 12, 2021

That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s Clinical Research Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharma companies seem to be gradually improving on this. Thanks very much’.”.

Trials 132

Trials Research Pharma Companies Clinical Trials 132

XTalks

MAY 30, 2024

Over the years, his career has evolved from routine case processing at large pharma companies to a more strategic role in smaller settings, where he feels his impact more directly. He notes that the patient voice is critical, and with more involvement, patient advocacy groups will play an important role in clinical development.

Compliance 105

Compliance Clinical Development Pharmacy Development 105

pharmaphorum

MAY 4, 2022

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Once selected, Quris can in-license them, progress them through to phase 1 trials and, those that succeed, can be licensed to pharma companies.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143

Pharmaceutical Technology

NOVEMBER 25, 2022

In many cases, pharma companies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. The differences between adult and paediatric dosage forms are typically significant.

Manufacturing 130

Manufacturing Production Pharma Companies Development 130

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

pharmaphorum

SEPTEMBER 29, 2020

As summarised by The National Institutes of Health, this includes reducing the number of redundant clinical trials, enhancing the statistical strength of studies, reducing overall costs and risks, and improving study participant recruitment, all while triggering creativity and innovation between collaborators.

Research 132

Research Gene Editing Development Gene 132

pharmaphorum

MAY 7, 2021

This philosophy was behind Xperiome’s recent decision to split into two different functions – Raremark, a community where patients and carers can share their experiences of living with rare diseases, and Xperiome, which leverages those insights for pharma companies looking to develop drugs for these conditions. About the author.

Development 126

Development Pharma Companies Clinical Trials Clinical Trials 126

The Pharma Data

DECEMBER 21, 2020

The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

pharmaphorum

FEBRUARY 18, 2021

After a year in which the need for digital transformation in pharma reached white heat levels, the sector mustn’t cool off in 2021 and revert to business-as-usual. A return to normal is the longed for goal for many of us, but pharma companies must decide what their future normal should look like.

Medicine 109

Medicine Pharma Companies Development Clinical Trials 109

Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

Pharmaceutical Technology

JUNE 15, 2023

Clinical trial monitoring Completing clinical studies more quickly can mean critical medicines and treatments reach patients faster. Companies that combine rapid innovation with speedy but safe trials can gain a multifaceted competitive advantage.

Pharma R&D 130

Pharma R&D Production Manufacturing Development 130

Delveinsight

MARCH 1, 2021

The US FDA is working with stakeholders, including patients, patient advocates, product developers, and researchers, to fulfill its multiple, complex responsibilities towards improving rare disease clinical development. However, in the end, developing therapies and drugs for rare diseases is a team sport and a team effort.

Marketing 52

Marketing Clinical Trials Clinical Trials Drugs 52

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

JUNE 8, 2021

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. From 2008 to 2017, he served as an executive director of the clinical development department at Celgene (now part of Bristol-Myers Squibb).

Marketing 105

Marketing Drugs Development Regulation 105

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Regulators may not require the large phase 3 trials needed to approve completely new drugs, as safety is proven.

Insulin 52

Insulin Drugs Production Marketing 52

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. The Gastroparesis market size in the 7MM was found to be USD 3,170.01 Another U.S.

Marketing 54

Marketing Trials FDA Approval Clinical Development 54

pharmaphorum

OCTOBER 26, 2022

Every pharma company developing treatments for new diseases is contributing to some degree to better global health. We design our clinical development strategy and the trials with this aim in mind.”. But rare diseases are a particularly important and challenging focus area.

Development 96

Development Trials Marketing Life Science 96

pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. Involving patients in discussions.

Clinical Trials 101

Clinical Trials Clinical Trials Trials Clinical Research 101

Pharma Marketing Network

JUNE 8, 2020

As Bob and I were talking about our experiences, almost every strategic kickoff meeting I would go to, the client at the pharma company or whatever would say, you know there’s X amount of people who suffer with this condition but it’s underappreciated, under acknowledged, under diagnosed and under treated. Bob (83Bar): Yes, we do.

Doctor 40

Doctor Doctors Clinical Trials Clinical Trials 40

Roots Analysis

MAY 21, 2024

Due to which, several big pharma companies and other industry stakeholders are actively contributing towards development of protein degradation therapies and technologies, contributing towards growth of targeted protein degradation market.

Protein 40

Protein Marketing Development Antibody 40

Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline.

Marketing 94

Marketing Pharma Companies Development Hormones 94

Delveinsight

JULY 29, 2020

WHO is tracking vaccine development worldwide which are in different phases, similarly in India around seven leading companies working independently and in collaboration are in various Phases of clinical trials. The first part of Phase-1 trials commenced at PGIMS, Rohtak on July 17. Zydus Cadila ( ZyCoV-D ).

Vaccination 62

Vaccination Vaccine Clinical Trials Clinical Trials 62

pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past.

Antibody 91

Antibody Life Science Development Drugs 91

pharmaphorum

JULY 5, 2021

The handover comes four years after Pamplona Capital Management bought the company for around $5 billion, and just a few weeks after lab tech company Thermo Fisher Scientific agreed to acquire another CRO – PPD – in a deal valued at $17.4

Clinical Trials 64

Clinical Trials Clinical Trials Trials Regulation 64

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Calliditas said part A of the global phase 3 NeflgArd clinical trial has met its target, measuring the effect of Nefecon versus placebo in patients with the disease known as IgAN for short. Rare disease progress.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

FEBRUARY 2, 2021

The current Viela pipeline includes four therapeutic candidates currently in nine development programs. Besides Uplizna, VIB4920, VIB7734 and VIB1116 are the three candidates in different stages of clinical development. The trial failed to meet primary endpoint or other secondary endpoints. .

Drugs 40

Drugs Clinical Trials Clinical Trials Development 40

XTalks

JUNE 25, 2024

In the past two years, the industry has faced considerable challenges due to a constrained financing environment, forcing many emerging and early-stage biotech companies to restructure their operations, merge with other companies or narrow their research and development (R&D) efforts by shelving certain assets.

Pharma Companies 52

Pharma Companies Production FDA Approval Vaccination 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. 1. -- -->. -- [if lte IE 8]--> .

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. What can be expected from ongoing clinical trials in the Synovial sarcoma landscape? million in 2020 in the 7MM. million in 2017.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

Delveinsight

AUGUST 4, 2021

Similarly, many clinical trials are going on to further strengthen the therapeutic pipeline for different Neurological Conditions. The companies in the Parkinson’s Disease Therapeutics Market include Cortexyme, Cerevel Therapeutics, Amneal Pharmaceuticals, Pharma Two B, Cerevance, AbbVie, Theranexus, and others.

Marketing 98

Marketing Genetics Development Clinical Development 98